16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of secukinumab in patients with active
ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs,
DMARDs and / or TNFα inhibitor therapy.